Skip to content

Study · Case report or series · n = 1 · 2026

2 results

Oral Semaglutide Further Reduced LDL Cholesterol in a Patient with Familial Hypercholesterolemia Treated with Statins, Ezetimibe, and Evolocumab.

Tada H, Takamura M

Internal medicine (Tokyo, Japan)28 Aug 2025

PMID40866272 (opens in a new tab)PMCIDPMC13106759 (opens in a new tab)DOI10.2169/internalmedicine.6198-25 (opens in a new tab)PepBankPUB-40866272
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a woman with heterozygous familial hypercholesterolemia on statins, ezetimibe and evolocumab, adding oral semaglutide further reduced LDL cholesterol.

    In plain wordsIn one woman with familial hypercholesterolemia, adding oral semaglutide lowered LDL cholesterol further.

    Peptide
    Semaglutide
    Outcome
    DecreaseLDL cholesterol
    Study

    n = 1

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.
    1 context sentence
    Summary · context
    We present the case of a woman with heterozygous familial hypercholesterolemia with a history of myocardial infarction at 53 years of age. Her initial low-density lipoprotein (LDL) cholesterol level was 312 mg/dL, which was reduced to ~50 mg/dL using statins, ezetimibe, and evolocumab.
  2. 02HumanCase report or seriesEfficacy outcome

    In a woman with heterozygous familial hypercholesterolemia and diabetes, oral semaglutide contributed to good management of diabetes.

    In plain wordsIn one woman with diabetes, oral semaglutide contributed to good diabetes control.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedDiabetes management
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · oralAs given in this study (human).

    Source sentences

    Summary
    We introduced oral semaglutide, which contributed not only to the good management of diabetes, but also to the further reduction of LDL cholesterol in addition to intensive LDL-lowering therapies, including statins, ezetimibe, and evolocumab.
    1 context sentence
    Summary · context
    We present the case of a woman with heterozygous familial hypercholesterolemia with a history of myocardial infarction at 53 years of age. Her initial low-density lipoprotein (LDL) cholesterol level was 312 mg/dL, which was reduced to ~50 mg/dL using statins, ezetimibe, and evolocumab.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.